Dimensional Fund Advisors LP Has $1.99 Million Position in Cabaletta Bio, Inc. $CABA

Posted by George Bondi on Aug 14th, 2026

Dimensional Fund Advisors LP raised its position in Cabaletta Bio, Inc. (NASDAQ:CABA – Free Report) by 63.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 740,648 shares of the company’s stock after purchasing an additional 288,609 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Cabaletta Bio were worth $1,990,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Private Advisor Group LLC grew its holdings in shares of Cabaletta Bio by 22.4% during the first quarter. Private Advisor Group LLC now owns 18,025 shares of the company’s stock worth $48,000 after purchasing an additional 3,300 shares during the last quarter. SG Americas Securities LLC raised its holdings in Cabaletta Bio by 44.0% in the 4th quarter. SG Americas Securities LLC now owns 30,629 shares of the company’s stock valued at $67,000 after buying an additional 9,365 shares during the last quarter. Kestra Advisory Services LLC bought a new position in Cabaletta Bio in the 1st quarter valued at approximately $32,000. China Universal Asset Management Co. Ltd. bought a new position in Cabaletta Bio in the 4th quarter valued at approximately $34,000. Finally, ANTIPODES PARTNERS Ltd acquired a new stake in Cabaletta Bio during the 4th quarter worth approximately $38,000.

Cabaletta Bio Price Performance

Shares of CABA opened at $2.71 on Friday. The business has a 50-day moving average of $2.90 and a 200-day moving average of $3.06. The company has a market capitalization of $441.87 million, a price-to-earnings ratio of -1.38 and a beta of 3.30. Cabaletta Bio, Inc. has a 1 year low of $1.40 and a 1 year high of $4.23.

Cabaletta Bio (NASDAQ:CABA – Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.03. As a group, sell-side analysts anticipate that Cabaletta Bio, Inc. will post -1.38 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on CABA. Wall Street Zen lowered shares of Cabaletta Bio from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cabaletta Bio in a research note on Friday, July 17th. Jefferies Financial Group reiterated a “buy” rating on shares of Cabaletta Bio in a report on Wednesday, June 3rd. Wells Fargo & Company boosted their price objective on shares of Cabaletta Bio from $2.00 to $4.00 and gave the stock an “equal weight” rating in a research note on Friday, May 15th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $30.00 price objective on shares of Cabaletta Bio in a report on Monday, May 4th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $15.50.

Check Out Our Latest Stock Analysis on CABA

About Cabaletta Bio

(Free Report)

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.